TITLE

FDA Heightens Warnings on Chantix

PUB. DATE
March 2008
SOURCE
Travel Medicine Advisor;Mar2008, Vol. 18 Issue 3, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has strengthened its warning on the stop smoking drug varenicline, Chantix from Pfizer. It says that the agency has issued an Early Communication regarding reports of changes in behavior, depressed mood, suicidal ideation, and suicidal behavior in patients taking the drug. Accordingly, the company has been asked by the FDA to take up the prominence of the warnings on the package label.
ACCESSION #
31143289

 

Related Articles

  • US FDA warns Pfizer over tardy pharmacovigilance.  // Reactions Weekly;6/19/2010, Issue 1306, p2 

    The article reports on the 12-page letter issued by the U.S. Food and Drug Administration (FDA) to Pfizer company in June 2010 which addresses the company's failure to report potential drug side effects in a timely fashion.

  • Clinicians React to FDA's Gadolinium Warnings.  // Renal & Urology News;Oct2010, Vol. 9 Issue 10, p35 

    The article reports on the requirements of the U.S. Food and Drug Administration (FDA) for the new warnings on the labels of gadolinium-based contrast agents (GBCAs) including Magnevist, Omniscan, and Optimark that will indicate the risk of nephrogenic system fibrosis (NSF) if taken by the...

  • FDA Updates Labeling for Erectile Dysfunction Drugs.  // FDA Consumer;Sep/Oct2005, Vol. 39 Issue 5, p3 

    Reports on an approval by the U.S. Food and Drug Administration on updated labeling for several erectile dysfunction drugs, as of September 2005. Reason behind the updating of labeling; Advice given by the FDA to patients taking these medicines; Effect of these medicines on people with prior...

  • FDA warns of potential intestinal issues with olmesartan medoxomil.  // Cardiology Today;Aug2013, Vol. 16 Issue 8, p18 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the labeling changes to drugs containing olmesartan medoxomil, issuing a warning on its potential for intestinal problems.

  • FDA adds boxed warning to propylthiouracil. Kalwaitis, Katie; Southall, Jennifer // Endocrine Today;May2010, Vol. 8 Issue 5, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has added a boxed warning to propylthiouracil to include risks of severe liver injury and acute liver failure.

  • Boxed warning now required for antiphychotics for elderly with dementia.  // Primary Care Reports;Aug2008 Pharmacology Watch, p1 

    This article reports on a policy issued by the U.S. Food and Drug Administration in 2008 requiring a boxed warning for conventional antipsychotics. The policy concerns with an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The policy expands the warning on...

  • Contra Pfizer. Healy, David // Ethical Human Psychology & Psychiatry;Fall/Winter2005, Vol. 7 Issue 3, p181 

    Against a background of longstanding concerns that antidepressants may trigger suicidality, the Food and Drug Administration (FDA) in 2004 convened two committees to review the issues. Prior to the second meeting Pfizer posted an extensive ad hominem attack on me on FDA's website. There was no...

  • Pfizer criticised over delay in admitting drug's problems. Lenzer, Jeanne // BMJ: British Medical Journal (International Edition);10/23/2004, Vol. 329 Issue 7472, p935 

    Reports that the drug company Pfizer delayed announcing negative data about its painkiller valdecoxib (Bextra), according to Curt Furberg from the Food and Drug Administration's Data Safety and Risk Management Advisory Committee. Allegation from Furberg that Pfizer left out important details...

  • FDA Heightens Warnings on Chantix.  // Infectious Disease Alert;Mar2008, Vol. 27 Issue 6, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has reinforced its warning on varenicline, a stop smoking drug from Pfizer under the trade name Chantix, due to its association with neuropsychiatric symptoms. It states that the FDA has asked the company to include these...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics